Compare TG Therapeutics Inc (TGTX) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Toyota Motor Corp — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Toyota Motor Corp trades at $186.82 (market cap $221.79B). The key difference: Toyota Motor Corp is far larger — about 29× TG Therapeutics Inc's market cap, and Toyota Motor Corp pays a 3.3% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TM | |
|---|---|---|
Market Cap | $7.64B | $221.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $248.29 |
52-Week Low | $26.94 | $166.50 |
Enterprise Value | $7.84B | $414.06B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Toyota Motor trades at $188.22, down 0.3% over 24 hours, with a bullish technical signal and strong fundamentals including a low P/E of 8.53 and consistent earnings beats. Recent news highlights a major vehicle recall and mixed quarterly results, with revenue growth offset by cost pressures.
The outlook is cautiously optimistic given attractive valuation and hybrid vehicle strength, but risks include recall costs, China sales weakness, and macroeconomic headwinds. Analyst consensus leans Hold, reflecting balanced growth prospects against near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
